Group 1: Palvella Therapeutics Inc. (PVLA) - Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with no FDA-approved treatments [2] - Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and has a multi-billion-dollar market opportunity if approved [2] - The stock rose from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, before pulling back to $99.88 [3] Group 2: Cidara Therapeutics Inc. (CDTX) - Cidara is developing a preventive therapy for influenza and has agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion [4] - The stock was trading at $18.98 when profiled on November 21, 2024 [4] Group 3: Celcuity Inc. (CELC) - Celcuity is focused on targeted therapies for oncology, with its lead drug candidate Gedatolisib aimed at breast and prostate cancers [5] - The stock increased from $12.60 on December 4, 2024, to an all-time high of $112.64 on December 12, 2025, before retreating to $99.16 [6] Group 4: Nanobiotix (NBTX) - Nanobiotix is a late-stage clinical biotechnology company developing physics-based therapies for cancer [7] - Its lead candidate, NBTXR3, is undergoing a phase III study for head and neck squamous cell carcinoma, with interim data expected in the first half of 2027 [8] - The stock rose from $12.23 on September 19, 2025, to a high of $30.35 on October 13, 2025, before trading around $21 [10] Group 5: Terns Pharmaceuticals Inc. (TERN) - Terns Pharma is developing small-molecule candidates for serious diseases, with TERN-701 targeting chronic myeloid leukemia [12] - Recent data showed a 75% major molecular response rate among patients receiving higher doses [13] - The stock increased from $5.98 on August 6, 2025, to an all-time high of $48.26 on December 10, 2025, before pulling back to around $40 [14] Group 6: DBV Technologies S.A. (DBVT) - DBV Technologies is developing an epicutaneous immunotherapy for food allergies, with its lead product, the VIASKIN Peanut patch, showing positive results in a phase 3 study [15] - The company aims to submit a Biologics License Application in the first half of 2026, with potential sales of $1.5 billion by 2030 if approved [15] - The stock rose from $10.64 on October 2, 2025, to a high of $26.18 on December 17, 2025, before trading around $19 [16] Group 7: Nutex Health Inc. (NUTX) - Nutex Health reported a significant turnaround from a $424 million net loss in 2022 to a $59 million net income for the nine months ended September 30, 2025 [17] - Revenue increased from $219 million in 2022 to $723.6 million in the first nine months of 2025 [17] - The stock rose from $33.56 on November 25, 2024, to a 52-week high of $193.07 before closing at $182.23 [18] Group 8: Inhibrx Biosciences Inc. (INBX) - Inhibrx is developing biologic therapies for cancer, with Ozekibart showing significant improvement in progression-free survival in chondrosarcoma [19] - The company plans to submit a biologics license application for Ozekibart in the second quarter of 2026 [20] - The stock rose from $18.35 on July 8, 2025, to an all-time high of $94.57 on December 22, 2025, before trading around $77 [21] Group 9: GRAIL Inc. (GRAL) - GRAIL focuses on early cancer detection with its Galleri test, which is not yet FDA-approved [23] - The company expects to submit a PMA for the Galleri test in Q1 2026 [23] - The stock increased from $48.50 on September 26, 2025, to a high of $115.76 on November 25, 2025, before trading around $88 [24] Group 10: Cogent Biosciences Inc. (COGT) - Cogent is developing precision therapies for genetically defined diseases, with Bezuclastinib being its lead candidate [25] - The company submitted its first NDA to the FDA for Non-AdvSM, with additional submissions planned for GIST and advanced systemic mastocytosis [26] - The stock rose from $7.25 on July 2, 2025, to a 52-week high of $43.73 on December 8, 2025, before easing back to around $35 [26] Group 11: Sol-Gel Technologies Ltd. (SLGL) - Sol-Gel has two FDA-approved products for dermatological conditions and is developing investigational products [27] - A phase III trial for SGT-610 is ongoing, with results expected in Q4 2026 [28] - The stock rose from $7.26 on May 7, 2025, to a high of $52.26 on October 6, 2025, before trading around $43 [28] Group 12: Zenas BioPharma Inc. (ZBIO) - Zenas is focused on therapies for autoimmune diseases, with Obexelimab in phase 3 trials for IgG4-RD [29] - Positive data from a phase 2 trial in multiple sclerosis showed a 95% reduction in new lesions [30] - The stock rose from $8.79 on December 17, 2024, to a high of $44.60 on December 24, 2025, before pulling back to around $35 [31]

Company Overview - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) specializes in developing small-molecule therapies for cancer and obesity, with key products including TERN-701 for chronic myeloid leukemia, TERN-501 for metabolic liver disease, and oral obesity treatments through TERN-601 and TERN-800 programs [2]. Recent Developments - On December 8, Terns Pharmaceuticals announced positive results for TERN-701, reporting a 64% major molecular response (MMR) rate in Phase 1 trials [2]. - The therapy achieved a 75% response rate at doses of 320 mg and above over a 24-week period, supporting these doses as the recommended Phase 2 doses [2]. - The Chief Medical Officer, Emil Kuriakose, highlighted a 36% durable molecular response (DMR) achievement rate by 24 weeks, indicating fast response kinetics and a favorable safety profile across all doses [2]. Market Performance - The stock of Terns Pharmaceuticals experienced significant volatility, rising from approximately $2 to around $48 before a slight pullback, indicating strong market interest and potential investor excitement [1].

Core Insights - The company, Turns Pharmaceuticals, is developing a new drug, Turn 701, for chronic myeloid leukemia (CML) that has shown approximately three times better efficacy than the current standard of care [1][3] - The drug has achieved a 75% major molecular response rate in patients who have undergone two or more prior treatments, indicating significant potential for those with limited options [3] - The company plans to initiate pivotal trials by the end of 2026, aiming to bring the drug to market soon [4] Market Potential - The current leading drug for CML is projected to reach peak sales of $4 billion, and the new drug is expected to have a larger addressable market due to its superior efficacy and the chronic nature of the disease [5][6] - Investors are optimistic about the drug's potential, contributing to a valuation close to $5 billion for the company [5] Development Focus - The company is primarily focused on bringing Turn 701 to market, with plans to share more information about additional assets in the pipeline in the future [6][7]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) experienced a significant stock increase of 53% over the past week, driven by positive results from its therapy candidate for chronic myeloid leukemia (CML) [1][5]. Group 1: Clinical Results - The therapy candidate TERN-701 showed a 64% improvement in the conditions of 63 enrolled patients after 24 weeks of treatment [2]. - A major molecular response rate of 74% was observed at a higher dosage of 320 mg [2]. - Out of the total enrollees, 55 patients continued treatment, while four dropped out due to disease progression [2][3]. Group 2: Market Response - Following the positive clinical results, Terns Pharmaceuticals received a price target increase of 107% to $58 from Oppenheimer, which also assigned an "outperform" rating to the stock [3]. - Oppenheimer highlighted the potential of TERN-701 as a "best-in-class" therapy in the CML market [3]. Group 3: Financial Developments - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares at an offer price of $40 each, including the underwriters' full exercise of their overallotment option covering 2.4 million shares [4][5]. - The funds raised will be allocated for the development and commercial launch of TERN-701, as well as for working capital and other corporate purposes [5].

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) experienced a significant stock increase of 53% over the past week, driven by positive results from its therapy candidate for chronic myeloid leukemia (CML) [1] Group 1: Clinical Results - The therapy candidate TERN-701 showed a 64% improvement in the conditions of 63 enrolled patients after 24 weeks of treatment [2] - A major molecular response rate of 74% was observed at a higher dosage of 320 mg [2] - Out of the 63 patients, 55 continued treatment, while four dropped out due to disease progression, three due to physician and patient decisions, and one due to adverse effects [2][3] Group 2: Market Response - Following the positive clinical results, investment firm Oppenheimer raised the price target for Terns Pharmaceuticals by 107% to $58, maintaining an "outperform" rating for the stock [3] - Oppenheimer highlighted the potential of TERN-701 as a "best-in-class" therapy in the CML market [3] Group 3: Financial Developments - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares at an offer price of $40 each, including the underwriters' full exercise of their overallotment option [4][5] - The funds raised will be allocated for the development, manufacturing, and commercial launch of TERN-701, as well as for working capital and other corporate purposes [5]

Core Points - Terns Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 18,687,500 shares at a price of $40.00 per share, resulting in gross proceeds of $747.5 million before deductions [1][3] - The offering was managed by Jefferies, TD Cowen, and Leerink Partners as lead book-running managers, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - The net proceeds from the offering will be utilized for research, clinical trials, development, and manufacturing of key product candidates, particularly TERN-701, as well as for working capital and general corporate purposes [3][5] Company Overview - Terns Pharmaceuticals is a clinical-stage oncology company focused on developing high-impact medicines, with its lead program TERN-701 being a selective allosteric BCR-ABL inhibitor aimed at improving treatment efficacy for chronic myeloid leukemia (CML) [5]

Core Points - Terns Pharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 16,250,000 shares at $40.00 per share, aiming for gross proceeds of $650 million [1] - The offering is expected to close on December 11, 2025, subject to customary closing conditions [1] - Terns has granted underwriters a 30-day option to purchase an additional 2,437,500 shares [1] Offering Details - Jefferies, TD Cowen, and Leerink Partners are the lead book-running managers for the offering, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - A shelf registration statement was filed with the SEC on December 9, 2025, and became effective on the same date [4] Use of Proceeds - The net proceeds from the offering will be used to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, as well as for working capital and general corporate purposes [3][6]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, necessitating investors to track developments closely [1] - The Haggerston BioHealth investing group provides insights into catalysts for investment decisions, including buy and sell ratings [1] Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1] - The investing group led by Ingham caters to both novice and experienced investors, offering forecasts and financial analyses for major pharmaceutical companies [1]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, necessitating investors to track developments closely [1] - The Haggerston BioHealth investing group provides insights into catalysts for investment decisions, including buy and sell ratings [1] Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1] - The investing group led by Ingham caters to both novice and experienced investors, offering forecasts and integrated financial analyses [1]